Azzad Asset Management Inc /Adv United Therapeutics Corp Transaction History

Azzad Asset Management Inc /Adv

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 01, 2024	SELL	$107.15 - $126.84 $579,467 - $685,950	-5,408 Closed	0 $0
Q4 2018 Apr 01, 2024	SELL	$101.4 - $128.73 $12,269 - $15,576	-121 Reduced 2.19%	5,408 $589 Million
Q3 2018 Apr 01, 2024	BUY	$113.81 - $129.46 $2,048 - $2,330	18 Added 0.33%	5,529 $707 Million
Q2 2018 Apr 01, 2024	BUY	$101.14 - $118.31 $557,382 - $652,006	5,511 New	5,511 $624 Million
Q1 2018 Apr 03, 2024	BUY	$107.21 - $151.94 $17,368 - $24,614	162 Added 5.91%	2,901 $326 Million
Q4 2017 Apr 03, 2024	BUY	$118.58 - $151.28 $4,980 - $6,353	42 Added 1.56%	2,739 $405 Million
Q3 2017 Apr 03, 2024	BUY	$114.6 - $136.81 $3,896 - $4,651	34 Added 1.28%	2,697 $316 Million
Q2 2017 Apr 03, 2024	BUY	N/A	144 Added 5.72%	2,663 $345 Million
Q1 2017 Apr 03, 2024	BUY	N/A	2,519 New	2,519 $341 Million
Q2 2014 Apr 03, 2024	SELL	N/A	-7,428 Closed	0 $0
Q1 2013 Apr 03, 2024	BUY	N/A	7,428 New	7,428 $452 Million
Q4 2012 Apr 08, 2024	SELL	N/A	-728 Reduced 8.85%	7,501 $401 Million
Q3 2012 Apr 08, 2024	BUY	N/A	8,229	8,229 $460 Million

723

60.9M

123K

104K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.